VPA Alleviates Neurological Deficits and Restores Gene Expression in a Mouse Model of Rett Syndrome

Weixiang Guo1✉, Keita Tsujimura2✉, Maky Otsuka I.3, Koichiro Irie2, Katsuhide Igarashi3✉,
Kinichi Nakashima2✉, Xinyu Zhao1✉

1 Department of Neuroscience and Waisman Center, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America,
2 Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan,
3 Life Science Tokyo Advanced Research center (L-Staff), Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan

Abstract

Rett syndrome (RTT) is a devastating neurodevelopmental disorder that occurs once in every 10,000–15,000 live female births. Despite intensive research, no effective cure is yet available. Valproic acid (VPA) has been used widely to treat mood disorder, epilepsy, and a growing number of other disorders. In limited clinical studies, VPA has also been used to control seizure in RTT patients with promising albeit somewhat unclear efficacy. In this study we tested the effect of VPA on the neurological symptoms of RTT and discovered that short-term VPA treatment during the symptomatic period could reduce neurological symptoms in RTT mice. We found that VPA restores the expression of a subset of genes in RTT mouse brains, and these genes clustered in neurological disease and developmental disorder networks. Our data suggest that VPA could be used as a drug to alleviate RTT symptoms.

Citation: Guo W, Tsujimura K, Otsuka I. M, Irie K, Igarashi K, et al. (2014) VPA Alleviates Neurological Deficits and Restores Gene Expression in a Mouse Model of Rett Syndrome. PLOS ONE 9(6): e100215. doi:10.1371/journal.pone.0100215

Editor: Nicoletta Landsberger, University of Insubria, Italy

Received January 20, 2014; Accepted May 23, 2014; Published June 26, 2014

Copyright: © 2014 Guo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the National Institutes of Health (NIH) (RO1MH080434 and RO1MH078972 to X. Zhao), the International Rett Syndrome Foundation (IRSF, 2755 to X. Zhao), and a Center grant from the NIH to the Waisman Center (P30HD03352 to X. Zhao). W. Guo was funded by a postdoctoral fellowship from University of Wisconsin Center for Stem Cells and Regenerative Medicine. This work was also supported in part by a Grant-in-Aid for Scientific Research (A) (to K. Nakashima), a Grant-in-Aid for Scientific Research on Innovative Areas: Foundation of Synapse and Neurocircuit Pathology (to K. Nakashima), all from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by an Intramural Research Grant (24-12) for Neurological and Psychiatric Disorders of NCNP (to K. Nakashima). This work was also supported in part by a Grant-in-Aid for Challenging Exploratory Research and a Grant-in-Aid for Scientific Research (B) (to K. Igarashi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: xzhao69@wisc.edu (XZ); kin1@scb.med.kyushu-u.ac.jp (KN); k-igarashi@hoshi.ac.jp (KI)

These authors contributed equally to this work.

Current address: State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China

Introduction

Rett syndrome (RTT) is a devastating neurodevelopmental disorder that occurs once in every 10,000–15,000 live female births. RTT patients develop normally until 6 to 18 months of age, but then regress rapidly, experiencing a wide range of neurological symptoms, including seizures, ataxia, and stereotypical hand movements with impairment of communication and cognition [1]. Seizure activity is common and reportedly occurs in up to 80% of patients.

RTT results largely from functional mutations in the X-linked MECP2 gene [2], which encodes a methylated CpG-binding protein that regulates transcription via epigenetic mechanisms [3]. Mutations and duplications of MeCP2 are also found in several other developmental disorders, including autism, demonstrating the functional importance of MeCP2 [4,5]. Mep2 null mutant (KO) mice develop similar symptoms as those seen in RTT patients; these mice have been used widely to study the etiology of human RTT [6,7,8]. Using RTT mice, we and others have shown that MeCP2 deficiency leads to altered expression of downstream effectors, resulting in impaired neuronal differentiation and maturation [9,10,11]. During the past decade, there have been extensive efforts devoted to understanding and treating RTT. However, for the most part we still lack effective and safe treatments.

Valproic acid (VPA) has been used clinically for decades as a treatment for mood disorders and seizures [12,13,14]. It was later also found to be an inhibitor for histone deacetylases, which are known to repress the expression of many genes [15,16]. Therefore, VPA could potentially affect a large number of genes, although its impact might be specific to different cell types. Despite the fact that its mechanism of action is not fully clear, VPA has been used or considered as a drug for a number of neurological diseases, including spinal muscular atrophy (SMA), Parkinson’s disease, Huntington’s disease, migraine, and dementia, as well as other diseases such as cancer and HIV infection. Since VPA exhibits broad efficacy but only mild and transient side effects, to date it has been used in more than 200 clinical trials for various diseases [12].

VPA has also been used to treat RTT patients, but mostly for seizure control [17]. Although one study found no beneficial effects [18], another study demonstrated a significant reduction in
seizures in RTT patients by VPA [19]. Some limited data have also revealed that VPA can improve behavioral deficits other than seizure in RTT, including verbal fluency [20] and decreased risk of fracture [21]. However, whether VPA can improve neurological symptoms has not been systematically assessed. VPA is known to restore MeCP2 deficiency-induced protein changes in a cultured cell system [22], yet whether VPA treatment can restore gene expression in MeCP2-deficient brains has not been tested.

In this study, we aimed to evaluate the therapeutic effect of VPA on symptomatic RTT mice. We treated Mecp2 KO mice with VPA at a peak of neurological symptoms and found that VPA could alleviate RTT-associated neurological symptoms. In addition, VPA partially restores global gene expression changes in MeCP2 KO mice. Interestingly, VPA specifically affects genes in the pathway related to neurological diseases. Thus our data support a potential therapeutic role for VPA in the treatment of RTT.

Materials and Methods

Ethics Statement

All animal procedures were performed according to protocols approved by the University of New Mexico and University of Wisconsin Animal Care and Use Committee. The Mecp2 KO mice (Mecp2tm1.1Jae) used in this study were created by deleting exon 3 containing the MBD domain of Mecp2 [23]. These mice have been bred over 40 generations on the ICR background. They start to show neurological symptoms between 5 and 7 weeks of age, and many die before 10 weeks of age, although some live as long as 17 weeks of age.

VPA Treatment

When mice reached 6 weeks old, they received daily injections of VPA (300 mg/kg; make 50 mg/ml VPA in saline) for 2 weeks (Fig 1). Three batches of mice were used. The first batch of mice included 3 groups of mice: WT control (n = 3), KO treated with VPA (KO+VPA, n = 5), and KO treated with saline (KO+saline, n = 4). We first did behavioral assessments during the VPA injection period. Immediately after the last injection, we dissected the brains from 3 mice per group and froze them in liquid N2 for RNA isolation. The rest of the mice were used for survival analysis. The second and third batches of mice included KO+VPA (n = 4) and KO+saline (n = 5); we did behavioral assessments during the injection period, and then we recorded the survival of mice. Therefore, total 9 KO+VPA and 9 KO+saline mice were assessed for behavioral symptom (Figure 1B) and 6 KO+VPA and 6 KO+saline mice were assessed for survival (Figure 1C).

Neurological Symptom Assessment

This assessment was carried out based on a published method [24]. We evaluated 6 core symptoms of RTT and scored the severity of symptoms: Score 0 indicated an absence of symptoms (wild-type all had 0); Score 1 indicated the presence of symptoms; Score 2 designated severe symptoms. Mice were also weighed at each scoring session. The sum of scores in all categories was used to represent the severity of symptoms. The symptoms we assessed and scoring criteria are as follow:

- Mobility: The mouse is observed when placed on a bench, then when handled gently. Score 0 = same as wild-type. Score 1 = reduced movement when compared to wild-type: extended freezing period when first placed on bench and longer periods spent immobile. Score 2 = no spontaneous movement when placed on the bench; mouse can move in response to a gentle prod or a food pellet placed nearby. (Note: mice may become more active when in their own cage environment.)
- Gait: Score 0 = same as wild-type. Score 1 = hind legs are spread wider than wild-type when walking or running with reduced pelvic elevation, resulting in a “waddling” gait. Score 2 = more severe abnormalities: tremor when feet are lifted, walks backwards or “bunny hops” by lifting both rear feet at once.
- Hind limb clasping: Mouse observed when suspended by holding base of the tail. Score 0 = legs splayed outwards. Score 1 = hind limbs are drawn towards each other (without touching) or
one leg is drawn in to the body. Score 2 = both legs are pulled in tightly, either touching each other or touching the body.

Tremor: Mouse observed while standing on the flat palm of the hand. Score 0 = no tremor. Score 1 = intermittent mild tremor. Score 2 = continuous tremor or intermittent violent tremor.

Breathing: Movement of flanks observed while animal is standing still. Score 0 = normal breathing. Score 1 = periods of regular breathing interspersed with short periods of more rapid breathing or with pauses in breathing. Score 2* = very irregular breathing: gasping or panting.

General condition: Mouse observed for indicators of general wellbeing, such as coat condition, eyes, body stance. Score 0 = clean shiny coat, clear eyes, normal stance. Score 1 = eyes dull, coat dull/un-groomed, somewhat hunched stance. Score 2* = eyes crusted or narrowed, piloerection, hunched posture.

Gene Expression Microarray Analysis

Half of the brain tissues from the first batch of mice (n = 3 mice/condition) were used for microarray analysis. Microarray analysis was performed following the manufacturer's instructions. First, total RNAs were purified using an RNeasy Mini kit (Qiagen) from half brains. First strand cDNAs were synthesized by incubating 5 μg of total RNA with SuperScript II reverse transcriptase (Invitrogen). After second-strand synthesis, the double-stranded cDNAs were purified using a MinElute Reaction Cleanup Kit (Qiagen) and labeled by in vitro transcription using a BioArray High Yield RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY, USA). The labeled cRNA was then purified using an RNeasy Mini kit (Qiagen) and treated with fragmentation buffer at 94°C for 35 min. For hybridization to a GeneChip Mouse Genome 430 2.0 Array (Affymetrix), 7.5 μg of fragmented cRNA probe was incubated with 50 pM control oligonucleotide B2, 1x eukaryotic hybridization control (1.5 pM BioB, five pM BioC, 25 pM BioD and 100 pM Cre), 0.1 mg/mL herring sperm DNA, 0.5 mg/mL acetylated BSA, and 1X manufacturer-recommended hybridization buffer in a 45°C rotator for 16 h. Washing and staining were performed in a GeneChip Fluidics Station (Affymetrix). The phycoerythrin-stained arrays were scanned as digital image files that were then analyzed with GeneChip Operating Software (Affymetrix). We selected the probe sets with the fold change of MeCP2KO-saline to wild-type more than 1.2 and a p-value under 0.05. Pathway analysis was performed using the Ingenuity Pathways Analysis software (Ingenuity Systems). Gene Ontology (GO) analyses were performed using Genespring software (Agilent Technologies).

Figure 2. VPA treatment restores the expression of a subset of genes in MeCP2 KO brains. (A) Scatter plots showing differential gene expression profiles among experimental conditions. (B) Heatmap showing 33 genes with >1.2-fold changes in the MeCP2 KO compared to WT brains and that were restored to <1.2-fold changes upon VPA treatment. doi:10.1371/journal.pone.0100215.g002
A  Neurological Diseases

B  Nervous System Development and Function
VPA Treatment of MeCP2-Deficient Mice

Figure 3. Ingenuity Pathway Analysis showing the two top networks restored by VPA in MeCP2 KO brains. The 310 gene restored by VPA in MeCP2 KO brains are mostly categorized into two networks: Neurological Disease network (A) and Nervous System Development and Function network (B). The colors indicate the direction of gene changes. Red, KO is higher than WT. Green, KO is lower than WT. The shapes of the boxes represent the functional categories of the genes. Inverted triangle: Kinase; Horizontally oval: Transcription Regulator, Vertical diamond: Enzyme, Square: Cytokine; Circle: Other; Bordered circle: Complex/Group, Vertically rectangle: G-protein Coupled Receptor; Horizontally diamond: Peptidase, Triangle: Phospatase.

doi:10.1371/journal.pone.0100215.g003

Results

VPA treatment can alleviate neurological symptoms in MeCP2-deficient mice

Since Meep2 mutant mice on C57B/L6 background are difficult to breed, we bred the Meep2 mutant [Jaenisch/MIT] line [23] onto ICR background for over 40 generations. The Meep2 heterozygote ICR female mice gave birth to significantly more surviving pups compared to their C57B/L6 counterparts therefore we used ICR mice for this study. Meep2 KO male mice on the ICR background started showing symptoms at about 5 weeks of age, and many of them died between 8 and 10 weeks of age, which is similar to Meep2 KO mice on C57B/L6 background. However, some of the Meep2 KO ICR males lived up to 17 weeks, which is significantly longer than their C57B/L6 counterparts. To determine whether VPA treatment might have a therapeutic effect on symptomatic KO mice, we decided to treat mice between 6 to 8 weeks of age, when all of them were showing clear RTT symptom, but before they were too sick to receive Intraperitoneal (i.p.) injections (Fig. 1A). Before daily injection of VPA, we first assessed the severity of neurological symptoms that are characteristics of RTT, including mobility, gait, hind limb clamping, tremor, breathing, and their general condition. We applied a published scoring system by setting the severity scale from 0 to 2: 0 is absent, 1 is present, and 2 is severe for each symptom [24]. Based on these criteria, all wild-type (WT) mice showed no symptoms, and therefore scored as 0. We found that the severity of neurological symptoms in saline-injected KO mice did not change significantly during the 2-week assessment and injection period (Figure 1B, black bar, one-way ANOVA with repeated measure, F_{6,46} = 2.085, p = 0.0724). On the other hand, the neurological scores of VPA-treated KO mice showed significant changes during the 2-week period (Figure 1B, white bar, one-way ANOVA with repeated measure, F_{6,46} = 2.685, p = 0.025), suggesting effects from VPA treatment on symptom development. More importantly, VPA treatment led to a significant reduction in the neurological severity score compared to saline-treated KO mice (Fig. 1B, two-way ANOVA with repeated measure, time and treatment interaction: F_{8,96} = 3.079, p = 0.0084; VPA treatment: F_{1,96} = 28.22, p < 0.0001). Among all six symptoms analyzed, gait (F_{1,96} = 8.344, p = 0.01), tremor (F_{1,96} = 16.42, p = 0.0009), breathing (F_{1,96} = 14.22, p = 0.0017), and general health condition (F_{1,96} = 5.311, p = 0.0321) showed significant improvement in VPA treated KO mice (Figure S1 in File S1). Mobility showed strong time and treatment interaction (F_{6,96} = 5.657, p < 0.0001) without significant effect by treatment alone. There was no significant difference in body weight between the treatment groups. We also assessed the survival of these mice both during and after the 2-week VPA treatment period. We found that although VPA treatment delayed the death of some of these KO mice, it had no significant effect on the overall lifespan of KO mice (Fig. 1C). Therefore, a short 2-week VPA treatment during the peak symptomatic period can reduce several key RTT neurological symptoms in a RTT mouse model.

VPA can rescue gene expression changes

To determine the molecular basis of symptom improvement, we collected brains from Mecp2 KO mice treated with VPA (KO+ VPA) or saline (KO+Saline) and WT mice at one day after the last VPA injection. We isolated RNA from these brains and subjected them to microarray analysis. The biological triplicates within the same experimental groups showed excellent reproducibility (Figure S2 in File S1).

Comparison among different experimental groups revealed significant expression changes in subsets of genes resulting from MeCP2 deficiency (KO+saline vs. WT), as well as restoration by VPA (KO+VPA vs. WT) (Table S1). To evaluate whether VPA could restore gene expression caused by MeCP2 deficiency, we selected genes that are significantly altered in MeCP2 KO mice (KO+saline vs WT), as well as restored by VPA treatment (KO+VPA vs. WT). The heat map demonstrates that 310 genes presented by 333 probe sets met these criteria (Fig 2B). Expression of some of these genes, such as Zkscan1, was reduced to near WT levels by VPA. Therefore, VPA can normalize the expression of a subset of genes to nearly WT levels in MeCP2-deficient brains.

Data deposition

The datasets that were generated and reported in this paper have been deposited into the National Center for Biotechnology Information GEO database through accession number GSE56780.

Table 1. Top Networks Restored by VPA Treatment.

| ID | Top Diseases and Functions | Score |
|----|---------------------------|-------|
| 1  | Cancer, Neurological Disease, Connective Tissue Disorders | 40 |
| 2  | Organismal Injury and Abnormalities, Cellular Growth and Proliferation, Cellular Movement | 35 |
| 3  | Nervous System Development and Function, Molecular Transport, Behavior | 35 |
| 4  | Cellular Function and Maintenance, Hematological System Development and Function, Inflammatory Response | 32 |
| 5  | Cellular Assembly and Organization, Cellular Function and Maintenance, Cell Morphology | 30 |

doi:10.1371/journal.pone.0100215.s001
VPA treatment restores expression of a subset of genes involved in neurological disorders

To determine the types of genes whose expression was restored by VPA in the context of MeCP2 deficiency, we subjected these 310 genes to Ingenuity Pathway Analysis and found that the top networks affected by VPA (Table 1 and Table S2) include Neurological Diseases (Fig 3A) and Nervous System Development and Function (Fig 3B). When we analyzed the biological functions of these 310 genes, they were categorized into three main biological function groups: “Diseases and Disorders,” “Molecular and Cellular Functions,” and “Physiological System Development and Function” (Table 2). Interestingly, the “Diseases and Disorders” group contains the largest number of genes, with 83 genes in the category of “Neurological Disease” (Table 3). A Gene Ontology (GO) analysis also showed many of these genes are involved in important cellular functions (Table S3). Thus VPA restored genes in MeCP2-deficient brains mainly in the category of neurological disease and brain development.

We next used quantitative PCR to assess the expression levels of some of these VPA-restored genes (Figure 2B and Table S1). We confirmed that VPA treatment indeed restored the expression levels of Zkscan1, a transcription factor important for cell differentiation, and Cntn1, a cell adhesion protein with a central role in neuronal growth cones and axon guidance (Fig 4). We then selected a few interesting genes that also showed VPA restoration, but were just below the cut-off of our stringent data analysis criteria. Among these candidates that also showed restoration by VPA were Aebp2, a DNA-binding epigenetic regulator, and Kcnj16, a potassium channel (Figure S3 in File S1). Therefore, in MeCP2-deficient brains, VPA could restore the expression of a subset of genes involved in neurological disease and brain development.

Discussion

In this study we explored whether VPA treatment could alleviate neurological symptoms of RTT. We discovered that VPA treatment during the symptomatic stage of disease significantly reduced neurological deficits in RTT mice. We also showed that VPA can restore the expression of a subset of neurological disease-related genes resulting from MeCP2 deficiency.

Although VPA has been used to treat seizures in a small number of RTT patients, its effect on neurological symptoms has not been well documented. The fact that treatment with VPA during the peak symptomatic stage of the disease could significantly improve neurological symptoms in MeCP2 KO mice is exciting. Our data suggest VPA may be a promising drug for the treatment of RTT. One remaining question is whether VPA treatment either before or during the early onset of symptoms may lead to additional improvements. Moreover, we only treated mice for two weeks. It is possible that longer treatment might bring more relief of symptoms and a longer lifespan. However, i.p. injection at the symptomatic stage may cause more stress to the animals, so the VPA injection route will have to be optimized (e.g. oral administration).

Since VPA inhibits HDACs, which are known to be involved in the suppression of many genes, we expected to detect a great many genes whose expression level is altered by VPA in the brain; however, we could only find 310 genes with a significant restoration of their expression levels in response to the VPA treatment. This could be due in part to the fact that we used brain tissues containing different cell types, which may respond to VPA differently. It is also likely that the brain’s compensatory changes may mask the effect of VPA. Nevertheless, it is worth noting that the 310 genes restored by VPA are clustered in the network of Neurological Disease and Nervous System Development (Figure 3, Table 1, Table S2), and 83 of these genes are in the Disease and Disorder functional group (Table 2). Many of these genes have been linked to human diseases. For example, a mutation inCNTN1, a neural adhesion protein, leads to a familial form of lethal congenital myopathy [25]. Transcription factor FOXP1 deletion and overexpression are both linked to autism [26,27], and transcription factorZKSCAN1 is associated with Wolf-Hirschhorn syndrome with intellectual disability (www.genecards.org). The molecular and cellular biological function group restored by VPA included molecular transport, lipid metabolism, small molecule biochemistry, and cell morphology. The restoration of cell morphology may be an important application for rescuing the impaired dendritic development in MeCP2-deficient brains that we and others have observed [9]. The potential action of VPA in molecular transport, metabolism, and biochemistry is also very interesting because MeCP2 was recently found to play a role in RNA splicing [28,29] and nuclear size determination [30]. In addition, as a next step, it would be interesting to explore the cell type-specific changes of some of the candidate genes we have discovered. We also believe we may have missed some other genes restored by VPA due to the stringency of our data analysis. For example, Aebp2, an epigenetic DNA-binding protein involved in Hirschsprung’s disease and Waardenburg syndrome [31], and Kcnj16, a potassium channel involved in respiratory response to hypoxia during breathing [32], showed VPA-restored expression changes, but the p value was greater than 0.05. It is likely that
changes in other genes were masked by the complexity of brain tissues we used. Previous studies have found hundreds of genes are changed in the hypothalamus or cerebellum of MeCP2 KO mice [33,34]. A recent study has identified 127 genes were altered in the striatum of MeCP2 KO mice [35]. A comparison of our data and these data showed a small percentage of the genes are shared. For example, among 383 genes altered in the hypothalamus of Mecp2 KO mice[34], 8 of them are in the 621 genes we found altered in Table 3.

**Table 3. Neurological Disease Genes Restored by VPA.**

| Gene Symbol | Gene Title |
|-------------|------------|
| 2010111101Rik | RIKEN cDNA 2010111101 gene |
| Adamt4 | a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 4 |
| Adamt1l | ADAMTS-like 1 |
| Adra2a | adrenergic receptor, alpha 2a |
| Bcl11a | B cell CLL/lymphoma 11A (zinc finger protein) |
| Bub3 | budding uninhibited by benzimidazoles 3 homolog (S. cerevisiae) |
| Cdcl4b | CTC14 cell division cycle 14B |
| Cds1 | CDP-diacylglycerol synthase 1 |
| Chnn6 | cholinergic receptors, nicotinic, alpha polypeptide 6 |
| Ctn1 | contactin 1 |
| Ctip3a1 | collagen, type III, alpha 1 |
| Ctip4a2 | collagen, type IV, alpha 2 |
| Ctip5a2 | collagen, type V, alpha 2 |
| Crym | crystallin, mu |
| Cyp51 | cytochrome P450, family 51 |
| Dab1 | disabled 1 |
| Dnajc1 | DnaJ (Hsp40) homolog, subfamily C, member 1 |
| Dusp5 | dual specificity phosphatase 5 |
| Ednrb | endothelin receptor type B |
| Efrn5 | ephrin A5 |
| Fat4 | FAT tumor suppressor homolog 4 (Drosophila) |
| Flbn1 | fibulin 1 |
| Fhdc1 | FH2 domain containing 1 |
| Foxp1 | forkhead box P1 |
| Gabra3 | gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 |
| Galmt | UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylglucosaminyltransferase 7 |
| Gia1 | glycine receptor, alpha 1 subunit |
| Gpr126 | G protein-coupled receptor 126 |
| Hcn1 | hyperpolarization-activated, cyclic nucleotide-gated K+1 |
| Hr33 | histamine receptor H3 |
| Ier5 | immediate early response 5 |
| Kazn | kazrin, periplakin interacting protein |
| Kcnal1 | potassium voltage-gated channel, shaker-related subfamily, member 1 |
| Kcnal2 | potassium voltage-gated channel, shaker-related subfamily, member 2 |
| Kcnal3 | potassium voltage-gated channel, shaw-related subfamily, member 1 |
| Krt1 | KRT1, ankyrin repeat containing |
| Ldfr | low density lipoprotein receptor |
| Lgals1 | lectin, galactose binding, soluble 1 |
| Malat1 | metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) |
| Marcksl | MARCKS-like 1 |
| Met | met proto-oncogene |
| Mtmr9 | myotubularin related protein 9 |

**Table 3. Cont.**

| Gene Symbol | Gene Title |
|-------------|------------|
| Ndr1 | N-myc downstream regulated gene 1 |
| Nfatc2 | nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 2 |
| Nfib | nuclear factor, interleukin 3, regulated |
| Nmb | neuromedin B |
| Nppa | natriuretic peptide type A |
| Nrip1 | nuclear receptor interacting protein 1 |
| Ntrk3 | neurotrophic tyrosine kinase, receptor, type 3 |
| Opr1 | opioid receptor, kappa 1 |
| Pag6 | progestin and adipoQ receptor family member VI |
| Pcl | piccolo (presynaptic cytomatrix protein) |
| Pcsk1 | proprotein convertase subtilisin/kexin type 1 |
| Pim3 | pro viral integration site 3 |
| Plcb4 | phospholipase C, beta 4 |
| Pnkd | paroxysmal nonkinesiologic dyskinesia |
| Pparc1a | peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
| Ppp1r1 | protein phosphatase 1, regulatory (inhibitor) subunit 1A |
| Prdm2 | PR domain containing 2, with ZNF domain |
| Prkcg | protein kinase C, gamma |
| Rims3 | regulating synaptic membrane exocytosis |
| Scn1a | sodium channel, voltage-gated, type I, alpha |
| Sema3f | sema domain, immunoglobulin domain (lg), short basic domain, secreted, (semaphorin) 3F |
| Sbp2 | S-phase kinase-associated protein 2 (p54) |
| Slc16a2 | solute carrier family 16 ( monocarboxylic acid transporters), member 2 |
| Slc15a1 | solute carrier organic anion transporter family, member 3A1 |
| Smox | small muscle protein, X-linked |
| Sst | somatostatin |
| Sstr3 | somatostatin receptor 3 |
| Sv2c | synaptic vesicle glycoprotein 2c |
| Taok1 | TAO kinase 1 |
| Tnbs3 | thrombospondin 3 |
| Tiparp | TCDD-inducible poly(ADP-ribose) polymerase |
| Tnc | tenascin C |
| Tmnt1 | troponin T1, skeletal, slow |
| Trps1 | trichorhinophalangeal syndrome 1 (human) |
| Tubb2b | tubulin, beta 2B class IIB |
| Vamp1 | vesicle-associated membrane protein 1 |
| Vav3 | vav 3 oncogene |
| Vcam1 | vascular cell adhesion molecule 1 |

doi:10.1371/journal.pone.0100215.t003

doi:10.1371/journal.pone.0100215.t003

VPA Treatment of MeCP2-Deficient Mice
the whole brain of MeCP2 KO mice and 5 of them are found in the 310 genes restored by VPA. It is not surprising that only small percentage of genes overlap among these data sets given the different original of the tissues and mixed composition of cells in these brain regions. Future studies using pure populations of cells will likely reduce false negatives and uncover more VPA-restored genes in specific brain cell types. VPA may affect different sets of genes in specific cell types, which will be a valuable avenue of study to pursue in the future.

Supporting Information

Table S1 VPA restored Genes in MeCP2 KO Brains.

Table S2 Top Networks and Genes Restored by VPA Treatment.

Table S3 Gene Ontology Analysis of VPA-Restored Genes in MeCP2 KO Brains.

File S1 This file contains 3 supplemental figures (Figure S1, Figure S2, and Figure S3). Figure S1. VPA treatment rescues certain pathological symptoms in MeCP2 KO mice. Figure S2. Scatter plots showing reproducibility in gene expression profiles among biological triplicates within each experimental condition. Figure S3. Quantitative PCR data showing restoration of Aebp2 and Kcnj16 genes in MeCP2 KO brains by VPA treatment.

Author Contributions

Conceived and designed the experiments: XZ KN. Performed the experiments: WG KT K. Irie. Analyzed the data: WG KT MOI K. Igarashi KN XZ. Wrote the paper: KN XZ K. Igarashi. Final approval of the version to be published: KN XZ K. Igarashi.

References

1. Kriaucionis S, Bird A (2003) DNA methylation and Rett syndrome. Hum Mol Genet 12 Suppl 2: R221–R227.
2. Amir RE, Van den Veyver IB, Wan M, Tran Q, Francke U, et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23: 185–188.
3. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6–21.
4. Amir RE, Van den Veyver IB, Wan M, Tran Q, Francke U, et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23: 185–189.
5. Neul JL (2012) The relationship of Rett syndrome and MECP2 disorders to autism. Dialogues in clinical neuroscience 14: 253–262.
6. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse MeCP2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27: 322–326.
7. Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27: 327–331.
8. Shahbazian M, Young J, Yuca-Paylor L, Spencer C, Antalffy B, et al. (2002) Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35: 243–254.
9. Smrt RD, Eaves-Egenes J, Barkho BZ, Sanistevan NJ, Zhao C, et al. (2007) MeCP2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol Dis 27: 77–89.
10. Smrt RD, Pfeiffer RL, Zhao X (2011) Age-dependent expression of MeCP2 in a heterogenous mosaic mouse model. Human molecular genetics 20: 1834–1843.
11. Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, et al. (2010) Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol 189: 127–141.
12. Chiu CT, Wang Z, Hambarger JG, Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacological reviews 65: 105–142.
13. Chateauieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. Journal of biomedicine & biotechnology 2010.
14. Koch-Weser J, Browne TR (1980) Drug therapy: Valproic acid. The New England journal of medicine 302: 661–666.
15. Gottlicher M (2004) Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Annals of hematology 83 Suppl 1: S91–92.
16. Grozinger CM, Schreiber SL, (2002) Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9: 3–16.
17. Faulkner MA, Singh SP (2013) Neurogenetic disorders and treatment of associated seizures. Pharmacotherapy 33: 330–343.

18. Huppke P, Kohler K, Brockmann K, Stettner GM, Gartner J (2007) Treatment of epilepsy in Rett syndrome. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society 11: 10–16.

19. Krajin N, Zupanic N, Oraczem J (2011) Epilepsy treatment in Rett syndrome. Journal of child neurology 26: 1429–1433.

20. Al Keilani MA, Carlier S, Groswasser J, Dan B, Deconinck N (2011) Rett syndrome associated with continuous spikes and waves during sleep. Acta neurologica Belgica 111: 328–332.

21. Leonard H, Downs J, Jian L, Bebbington A, Jacoby P, et al. (2010) Valproate and risk of fracture in Rett syndrome. Archives of disease in childhood 95: 444–446.

22. Vecsler M, Simon AJ, Amariglio N, Rechavi G, Gak E (2010) MeCP2 deficiency downregulates specific nuclear proteins that could be partially recovered by valproic acid in vitro. Epigenetics: official journal of the DNA Methylation Society 5: 61–67.

23. Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nature genetics 27: 327–331.

24. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315: 1143–1147.

25. Compton MR, Albrecht DE, Seto JT, Cooper ST, Ikovski B, et al. (2008) Mutations in contactin-1, a neural adhesion and neuromuscular junction protein, cause a familial form of lethal congenital myopathy. American journal of human genetics 83: 714–724.

26. Palumbo O, D’Agruma L, Mineur A, Palumbo P, Stallone R, et al. (2013) 3p14.1 de novo microdeletion involving the FOXP1 gene in an adult patient with autism, severe speech delay and deficit of motor coordination. Gene 516: 107–113.

27. Chien WH, Gau SS, Chen CH, Tsai WC, Wu YY, et al. (2013) Increased gene expression of FOXP1 in patients with autism spectrum disorders. Molecular autism 4: 23.

28. Young JI, Hong EP, Castle JC, Crespo-Barreto J, Bowman AR, et al. (2005) Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proceedings of the National Academy of Sciences of the United States of America 102: 17351–17358.

29. Maunakea AK, Chepelev I, Cui K, Zhao K (2013) Infragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell research.

30. Yazdani M, Deogracias R, Guy J, Poot RA, Bird A, et al. (2012) Disease modeling using embryonic stem cells: MeCP2 regulates nuclear size and RNA synthesis in neurons. Stem Cells 30: 2128–2139.

31. Kim H, Kang K, Ekram MB, Reh TY, Kim J (2011) Aebp2 as an epigenetic regulator for neural crest cells. PLoS One 6: e25174.

32. Trapp S, Tucker SJ, Gourine AV (2011) Respiratory responses to hypercapnia and hypoxia in mice with genetic ablation of Kir5.1 (Kcnj16). Experimental physiology 96: 451–459.

33. Ben-Shachar S, Chahrour M, Thaller C, Shaw CA, Zoghbi HY (2009) Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Human molecular genetics 18: 2431–2442.

34. Chahrour M, Jung SY, Shav G, Zhou X, Wong ST, et al. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320: 1224–1229.

35. Zhao YT, Goffin D, Johnson BS, Zhou Z (2013) Loss of MeCP2 function is associated with distinct gene expression changes in the striatum. Neurobiology of disease 59: 257–266.